Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn More
Lung cancer is a type of cancer that originates from lung cells. It is one of the most common cancers in the world and a major cause of cancer-related deaths. Alfa Cytology is a world leader in the research of cancer. With our extensive experience and advanced platform, we can provide the best solutions for lung cancer.
Lung cancer is mainly divided into two types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Smoking is the cause of most lung cancer, but non-smokers may also develop lung cancer. Prevention and early detection are crucial for combating lung cancer. The estimated number of new lung cancer cases and deaths in the United States in 2024 is 234, 580 and 125, 070, respectively.
The therapies for lung cancer include surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and a combination of these methods. The choice of method mainly depends on the stage or severity of the cancer, but other factors are also important, such as the overall health status and lung function of the body, as well as certain characteristics of the cancer itself.
Fig.1 The therapies for lung cancer. (Ashrafi, A., et al., 2022)
With the long-term research of disease targets and immune systems, targeted therapy and immunotherapy have become a new type of cancer therapy after surgery, chemotherapy, and radiotherapy because of their advantages of precision and small side effects. Here are a few examples of pharmaceutical companies and their drug development related to lung cancer.
Targets | Therapeutics | Company | Molecule Type | Phase |
---|---|---|---|---|
PD-1 | MK-3475 | Merck | Monoclonal antibody | |
B7-H3 IgG1 | Ifinatamab deruxtecan (MK-2400) | Merck | Antibody-drug conjugate | |
SEZ6 | ABBV-706 | Abbvie | Antibody-drug conjugate | |
TIGIT | Tiragolumab | Genentech | Monoclonal antibody |
Due to the complexity of lung cancer, developing effective lung cancer treatment methods faces certain challenges, such as high heterogeneity, genetic complexity, and acquired drug resistance. Therefore, Alfa Cytology is working on providing comprehensive solutions for lung cancer.
Non-Small Cell Lung Cancer (NSCLC)
NSCLC is the most common type of lung cancer. The growth and diffusion rate of NSCLC is usually slower than that of SCLC.
Small Cell Lung Cancer (SCLC)
Small cell lung cancer is not very common but extremely malignant and invasive, accounting for about 15-20% of lung cancer.
Alfa Cytology is an experienced comprehensive contract research organization (CRO). We are proud to provide a range of therapy development services for lung cancer, including but not limited to the following.
Alfa Cytology is committed to the research and study of cancer and provides one-stop services. Our cancer experts have many years of experience in the development of the latest therapies for lung cancer. If you are interested in our service, please contact us for more information.
Reference
For research use only.